(Arg)₉-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling.

ABSTRACT:

Background

Melanoma is a malignant tumor with high misdiagnosis rate and poor prognosis. The bio-targeted therapy is a prevailing method in the treatment of melanoma; however, the accompanying drug resistance is inevitable. SH2 superbinder, a triple-mutant of the Src Homology 2 (SH2) domain, shows potent antitumor ability by replacing natural SH2-containing proteins and blocking multiple pY-based signaling pathways. Polyarginine (Arg)₉, a powerful vector for intracellular delivery of large molecules, could transport therapeutic agents across cell membrane. The purpose of this study is to construct (Arg)₉-SH2 superbinder and investigate its effects on melanoma cells, expecting to provide potential new approaches for anti-cancer therapy and overcoming the unavoi

SUBMITTER: Liu AD 

PROVIDER: S-EPMC6034221 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature